通心络胶囊对不稳定型心绞痛患者的疗效及其机制研究  

A research on curative effect of Tongxinluo capsule on patients with unstable angina and its mechanism

作　　者：陈永斌[1] 李何鹏[1] 蔡志玲[2] 李若林[1] 

机构地区：[1]广西医科大学第一附属医院,广西南宁530021 [2]广西中医学院瑞康医院,广西南宁530001

出　　处：《中国中西医结合急救杂志》2012年第6期336-339,共4页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

基　　金：广西自然科学基金项目（桂科自0832150）

摘　　要：目的观察通心络胶囊对不稳定型心绞痛（UAP）患者血浆基质金属蛋白酶-2／9（MMP-2／9）水平的影响，初步探讨其治疗UAP的可能作用机制。方法采用前瞻性研究方法。将2010年2月至2011年6月本院收治的110例UAP患者按随机数字表法分为通心络组（58例）和常规组（52例）。常规组给予阿司匹林＋辛伐他汀＋硝酸酯类；通心络组在常规组药物治疗基础上加用通心络胶囊3粒（0．26g／粒），每日3次。同期选择100例年龄匹配的本院健康查体者作为健康对照。采用酶联免疫吸附试验（ELISA）测定患者治疗前及治疗1、2、3个月后的MMP-2／9浓度。结果UAP患者MMP-2／9（μg／L）水平均明显高于健康对照组（MMP-2：448．09±11．90比215．56±14．74。MMP-9：624．94±12．12比384．41±21．74，均P〈0．01）。通心络组与常规组治疗前MMP-2／9浓度相近（MMP-2：450．32±11．20比445．96±12．26，MMP-9：625．92±13．17比623．99±11．07，均P〉0．05）；随治疗时间延长，两组治疗后MMP-2／9水平均较本组治疗前一时间点明显降低（均P〈0．01），且通心络组降低程度明显大于同期常规组（P〈0．05或P〈0．01），以治疗3个月后降低更显著（MMP-2：281．74±21．15比363．17±14．19，MMP-9：407．83±10．05比523．05±9．78，均P〈0．01）。通心络组总有效率明显高于常规组（91．4％比76．9％，P〈0．05）。结论通心络胶囊具有稳定动脉粥样斑块，减轻患者临床症状的作用，其作用机制可能与降低UAP患者血浆的MMP-2／9水平有关。Objective To explore the possible mechanism of treating unstable angina pectoris （UAP）with Tongxinluo （TXL） through observing the effect of TXL on plasma levels of matrix metalloproteinase-2/9 （MMP-2/9） in patients with UAP. Methods A perspective study was conducted. One hundred and ten cases of patients with UAP admitted into the hospital between February 2010 and June 2011 were randomly divided into a TXL group （58 cases） and a conventional group （52 cases）. The patients in conventional group were treated with aspirin ＋ simvastatin ＋ nitrates ; TXL group was treated with the above conventional treatment and additionally 3 TXL capsules （0.26 g/capsule）, 3 times per day was applied. In the mean time, 100 age-matched healthy cases who had taken medical checkup in our hospital were selected as healthy control. Enzyme-linked immunosorbent assay （ELISA） was used to measure MMP-2/9 concentrations of the patients before treatment and 1, 2, 3 months after treatment in both groups, respectively. Results The plasma levels of MMP-2/9 （μg/L） in UAP patients were significantly higher than those in normal control cases （MMP-2 ： 448.09±11.90 vs. 215.56±14.74, MMP-9 ： 624.94±12.12 vs. 384.41±21.74, both P〈0.01） ; before treatment, the levels of MMP-2/9 were not significantly different between the TXL group and conventional group （MMP-2：450.32±11.20 vs. 445.96±12.26, MMP-9：625.92±13.17 vs. 623.99±11.07, both P〉0.05）. As the treatment progressed longer, the MMP-2/9 concentrations in both patient groups became lower compared to those before the treatment （all P〈0.01 ） ; moreover, the MMP-2/9 concentrations in the TXL group were significantly lower than those in the conventional group after treatment for 1, 2 and 3 months respectively （P〈0.05 or P〈0.01）, the most significant effect being at the time point of 3 months after treatment （MMP-2 ： 281.74±21.15 vs. 363.17±14.19, MMP-9：407.83±10.05 vs. 523.05±9.78, both P〈0.01）. The total effective

关 键 词：通心络 不稳定型心绞痛 基质金属蛋白酶 

分 类 号：R285.6[医药卫生—中药学] R459.7[医药卫生—中医学]